2-呋喃-2-基-2-氧代乙酸甲酯 | 33245-13-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-呋喃-2-基-2-氧代乙酸甲酯
• 中文别名: α-氧代呋喃-2-乙酸甲基酯；甲基α-氧代呋喃-2-乙酸酯
• 英文名称: furan-2-yl-oxo-acetic acid methyl ester
• 英文别名: methyl α-oxo(2-furyl)acetate；Furan-2-yloxoacetic acid ethyl ester；methyl 2-furanyl glyoxylate；2-(furan-2-yl)-2-oxoacetic acid methyl ester；2-(methoxy-2-oxoaceto)furan；methyl 2-(furan-2-yl)-2-oxoacetate；methyl 2-furylglyoxylate；2-Methoxalylfuran；Me-2FGA；M2FGA；methyl α-oxofuran-2-acetate；methyl 2-oxo-2-(2-furanyl)acetate；methyl alpha-oxo-2-furanacetate；Methyl alpha-oxofuran-2-acetate
• CAS: 33245-13-5
• 化学式: C₇H₆O₄
• mdl: MFCD09838570
• 分子量: 154.122
• InChiKey: ZHRNRBLRLWDFDH-UHFFFAOYSA-N

物化性质

• 熔点：
  39-40 °C
• 沸点：
  135 °C(Press: 20 Torr)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-呋喃-2-基-2-氧代乙酸甲酯 在 [RuCl2(benzene)]2 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、506.66 kPa 条件下， 反应 20.0h， 生成 methyl (S)-α-hydroxy(2-furyl)acetate
  参考文献：
  名称：

  TunePhos型手性二膦配体合成的简便分散策略及其在高对映选择性Ru催化加氢中的应用

  摘要：

  探索了一种方便，发散的策略，用于合成一系列模块化和可微调的C 3 -TunePhos型手性二膦配体及其在高效Ru催化的不对称加氢中的应用。对映选择性合成β-甲基手性胺和α-羟酸衍生物的ee值分别高达97％和99％。

  DOI：

  10.1021/jo702068w
• 作为产物：
  描述：

  α-氧代-2-呋喃乙酸 在 氯化亚砜 、 盐酸 作用下， 以 乙醚 、 水 为溶剂， 反应 2.83h， 以89%的产率得到2-呋喃-2-基-2-氧代乙酸甲酯
  参考文献：
  名称：

  Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents

  摘要：

  这项发明涉及一般式(I)的新杂环化合物及其与碱或酸形成的盐： 该发明还涉及制备这些化合物的方法，以及它们作为药物的用途，特别是作为抗菌剂。

  公开号：

  US20050245505A1

文献信息

• A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides
  作者：Margaret M. Faul、Leonard L. Winneroski、Christine A. Krumrich

  DOI：10.1016/s0040-4039(98)02594-5

  日期：1999.2

  Bisphenyl, Bisheteroaryl, indolylaryl and indolylcycloalkyl maleimides are prepared in one step and 67–99% yield by condensation of glyoxylate esters with acetamides using a 1.0 M solution of potassium tert-butoxide in THF. The mechanism of the reaction is discussed.

  使用1.0 M叔丁醇钾的THF溶液，通过乙醛酸酯与乙酰胺的缩合，可一步制备联苯，二异芳基，吲哚基芳基和吲哚基环烷基马来酰亚胺，收率67-99％。讨论了反应机理。
• Enantioselective addition of organozinc reagents to carbonyl compounds catalyzed by a camphor derived chiral γ-amino thiol ligand
  作者：Hsyueh-Liang Wu、Ping-Yu Wu、Ying-Ni Cheng、Biing-Jiun Uang

  DOI：10.1016/j.tet.2015.07.038

  日期：2016.5

  synthesis of the chiral camphor derived γ-amino thiol ligand 17 and its application in catalytic enantioselective carbon-carbon forming reactions through the addition of organozinc reagents to carbonyl compounds is described. The catalytic activity and enantioselectivity of ligand 17 is demonstrated in the enantioselective addition of various organozinc reagents to aldehydes and ketoesters, offering the corresponding

  在本文中，描述了手性樟脑衍生的γ-氨基硫醇配体17的设计和合成，以及通过向羰基化合物中添加有机锌试剂在催化对映选择性碳-碳形成反应中的应用。配体17的催化活性和对映选择性通过将各种有机锌试剂对映选择性加成到醛和酮酯中得到证明，从而以高收率和对映选择性提供相应的醇。还讨论了巯基在有机锌与醛的高度对映选择性1,2加成反应中的作用。
• Novel quinuclidine derivatives and medicinal compositions containing the same
  申请人：——

  公开号：US20040072863A1

  公开（公告）日：2004-04-15

  A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R 1 , R 2 and R 3 each independently represent a hydrogen or halogen atom, or a hydroxy group, a phenyl group, —OR 7 , —SR 7 , —NR 7 R 8 , —NHCOR 7 , —CONR 7 R 8 , —CN, —NO 2 , —COOR 7 or CF 3 group, or a strait or branched, substituted or unsubstituted lower alkyl group, wherein R 7 and R 8 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; or R 1 and R 2 together form an aromatic or alicyclic ring or a heterocyclic group. n is an integer from 0 to 4; A represents a group selected from —CH 2 —, —CH═CR 9 —, —CR 9 ═CH—, —CR 9 R 10 —, —CO—, —O—, —S—, —S(O)—, —S(O) 2 — and NR 9 , wherein R 9 and R 10 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; m is an integer from 0 to 8, provided that when m=0, A is not —CH 2 —; p is an integer from 1 to 2 and the substitution in the azonia bicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; R 4 represents a group of structure: (Formulae II) wherein R 11 represents a hydrogen or halogen atom, a hydroxy group, an alkoxy group, a nitro group, a cyano group, —CO 2 R 12 or —NR 12 R 13 , wherein R 12 and R 13 are identical or different and are selected from hydrogen and straight or branched lower alkyl groups, or a straight or branched, substituted or unsubstituted lower alkyl group; R 5 represents an alkyl group of 1 to 7 carbon atoms, an alkenyl group containing 2 to 7 carbon atoms, or a group of formula (III) wherein q=1 or 2 and R 11 iss a defined above; R 6 represents a hydrogen atom, a hydroxy group, a methyl group or a —CH 2 OH group; and X − represents a pharmaceutically acceptable anion of a mono or polyvalent acid. 1

  式(I)的化合物，其中B是苯环、含有一个或多个杂原子的5至10元杂芳香族基团，或萘基、5,6,7,8-四氢萘基、苯并[1,3]二氧杂环戊基或联苯基团；R1、R2和R3各自独立地表示氢或卤素原子，或羟基、苯基、—OR7、—SR7、—NR7R8、—NHCOR7、—CONR7R8、—CN、—NO2、—COOR7或CF3基团，或直链或支链、取代或未取代的低级烷基基团，其中R7和R8各自独立地表示氢原子、直链或支链的低级烷基基团，或一起形成脂环族环；或者R1和R2一起形成芳香族或脂环族环或杂环基团。n是0至4的整数；A表示选自—CH2—、—CH═CR9—、—CR9═CH—、—CR9R10—、—CO—、—O—、—S—、—S(O)—、—S(O)2—和NR9的基团，其中R9和R10各自独立地表示氢原子、直链或支链的低级烷基基团，或一起形成脂环族环；m是0至8的整数，条件是当m=0时，A不是— —；p是1至2的整数，并且氮杂双环环上的取代可以在2、3或4位，包括所有可能的不对称碳构型；R4表示具有结构：(式II)的基团，其中R11表示氢或卤素原子、羟基、烷氧基、硝基、氰基、—CO2R12或—NR12R13，其中R12和R13相同或不同，并选自氢和直链或支链的低级烷基基团，或直链或支链、取代或未取代的低级烷基基团；R5表示1至7个碳原子的烷基基团、含有2至7个碳原子的烯基基团，或具有式(III)的基团，其中q=1或2，且R11如上定义；R6表示氢原子、羟基、甲基或— OH基团；X-表示药物上可接受的单或多元酸的阴离子。
• Access to the noryohimban [6,5,6,5,6] ring system via an intramolecular furan Diels–Alder reaction
  作者：Demosthenes Fokas、Jean E. Patterson、Gregory Slobodkin、Carmen M. Baldino

  DOI：10.1016/s0040-4039(03)01179-1

  日期：2003.6

  Polycyclic indolic compounds containing the [6,5,6,5,6] ring system were prepared via an intramolecular furan Diels–Alder reaction of α,β-unsaturated amides generated by the N-acylation of 1-(2-furyl)-β-tetrahydrocarbolines. This chemistry can provide access to D(14)-noryohimban derivatives by exploiting the functionality on the C,D,E ring system of the corresponding cycloadducts.

  含有[6,5,6,5,6]环系统的多环吲哚化合物是通过分子内呋喃Diels-Alder反应制备的，该反应由1-（2-呋喃基）-的N-酰化反应生成的α，β-不饱和酰胺β-四氢咔啉。通过利用相应环加合物的C，D，E环系统上的官能团，该化学物质可提供对D（14）-去核育亨班衍生物的访问。
• .beta.-thiopropionyl-aminoacid derivatives and their use as
  申请人：SmithKline Beecham p.l.c.

  公开号：US06048852A1

  公开（公告）日：2000-04-11

  A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, heterocyclyl or heterocyclyl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, where m is 0 to 3, n is 1 to 3, each R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-4)alkyl and X is O, S(O).sub.x where x is 0-2, or a bond; R.sub.4 is hydrogen, or an in vivo hydrolysable acyl group; and R.sub.5 and R.sub.6 are independently hydrogen and (C.sub.1-6)alkyl or together represent (CH.sub.2).sub.p where p is 2 to 5. Some compounds are claimed per se.

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。